• DRAMP ID

    • DRAMP18065
    • Sequence

    • ILRWPWWPWRRK(αhelix)
    • Sequence Name

    • MBI-226(Omiganin)
    • Description

    • Synthetic 12-mer cationic peptide derived from indolicidin
    • Activity

    • Antibacterial
    • Medical use

    • the treatment of catheter-related infections
    • Stage of Development

    • Phase IIIb(Failure)
    • Comments

    • MBI-226 (Omiganin) showed promising results for secondary end points in phase IIIa trials, resulting in a 40% reduction of catheter colonization and a 50% decrease in tunnel infections, although its primary end point of a reduced rate of infections was not achieved (a 15% reduction was not statistically significant due to the small number of patients who contracted infections in this trial).In collaboration with Cadence Pharmaceuticals Inc., phase IIIb trials were initiated in the United States in August 2005 and in Europe in February 2006, using the renamed CPI-226 as a gel-based treatment for catheter infections.
    • Company

    • Migenix (Vancouver, BritishColumbia, Canada)
    • Target Organism

      • 90% inhibition of S.aureus(MIC=16μM)
    • Reference

      • Cationic antimicrobial peptides in clinical development, with special focus on thanatin and heliomicin.Eur J Clin Microbiol Infect Dis (2012)(PMID: 21964560)